Section
The 2024 EBMT activity report marks a major cellular therapy milestone, showing record allogeneic HCT, continued CAR-T expansion, and persistent disparities in donor use, pediatric activity, and country-level access.
EBMT’s 2024 report marks over one million reported stem cell transplants and continued rapid CAR-T growth, highlighting shifts in indications, donor use, and access across Europe.
A low-cost NGS-based MRD test detected hidden AML cells before transplant and strongly predicted worse survival after allogeneic stem cell transplantation.
miR-28 suppresses the emergence of ibrutinib resistance in ABC-DLBCL by disrupting clonal selection and dampening mitochondrial and mTOR signaling, with promising preclinical nanoparticle delivery results.
A study of leukemia patients found that Orca-T transplant therapy increases a regulatory-like CD4+FOXP3+Helios+ T-cell subset early after treatment, and this subset correlates with later T-cell activation, offering a potential biomarker for
In a prospective cohort, VWF and FVIII were significantly elevated in chronic graft-versus-host disease, tracked with disease activity, and showed moderate diagnostic performance for early cGvHD.
MD-265, a PROTAC MDM2 degrader, showed strong anti-leukemia activity in primary AML cells and mouse PDX models, outperformed a conventional MDM2 inhibitor, and spared normal stem cells relatively well.
Researchers found that IL-1β signaling drives growth, relapse, and bone damage in TCF3::HLF-positive B-ALL, suggesting IL-1β blockade may offer a new treatment strategy.
Routine oral rivaroxaban prophylaxis in ACTH-dependent Cushing syndrome was associated with no new VTE events after implementation and no bleeding complications, suggesting it is a safe and effective preventive strategy.
P85-Ab, an anti-EBV BNLF2b antibody test, showed excellent accuracy for suspected nasopharyngeal carcinoma and outperformed older EBV markers in most outpatient settings.
In adults with myelodysplastic neoplasms undergoing allogeneic transplantation, pretransplant cytoreduction modestly improved IPSS-M in some patients but did not improve post-transplant survival and was associated with higher non-relapse mo
A major 2026 study suggests donor age affects survival differently in haploidentical and matched unrelated stem cell transplants, offering a more practical framework for choosing the best donor.
Post-cycle 2 CBFB::MYH11 MRD best predicted outcomes in favorable-risk AML. Patients with levels ≥1% had higher relapse risk, and those receiving allo-HCT in CR1 had better 3-year disease-free survival than chemotherapy consolidation.
Adult AML with NUP98 rearrangements is a high-risk subtype marked by frequent FLT3-ITD and WT1 mutations, poor survival, and potential benefit from FLT3 inhibitors and stem cell transplant.
Single-cell profiling of WM during ibrutinib therapy revealed three tumor evolution patterns, a predictive WIP score, and T-cell dysfunction linked to resistance and disease progression.
Single-cell RNA sequencing suggests that childhood poverty exposure is associated with steroid-resistance signatures in leukemic blasts and adverse immune remodeling at diagnosis in standard-risk B-ALL.
In the GHSG HD21 trial, a validated ctDNA assay showed that MRD positivity after two treatment cycles strongly predicted inferior progression-free survival and improved early risk stratification, especially when combined with interim PET.
A PETHEMA registry study shows that specific mutations, especially DNMT3A, SF3B1, TP53, and WT1, meaningfully refine relapse-free survival after allo-HSCT in first-remission AML beyond ELN risk groups.
A single-center validation study suggests the CTCL-PRO-20 may provide a reliable, disease-specific measure of quality of life in patients with cutaneous T-cell lymphoma.
Anti-CD117 CAR T-cell therapy demonstrated potent elimination of malignant mast cells in preclinical models of advanced systemic mastocytosis, offering a potential new treatment approach for this aggressive disorder.
